"Much of this has taken place in the form of a gradual shift to specialty drugs for such conditions as cancers and autoimmune disorders, but recent developments have shown that primary care drugs may still have some steam left in them.???One market that still seems to be doing fairly well is chronic obstructive pulmonary disorder, which comprises emphysema and chronic bronchitis." . . . . .